



THE ORPHAN ONCOLOGY INNOVATOR

***ReLive: investigators meeting
and E-poster of the study design
during the 2015 EASL congress***

Paris (France), Copenhagen (Denmark), April 16, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an investigators' meeting (on April 24, 2015) will be held during the 50th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna (Austria) from April 22 to April 26, 2015, with ReLive investigators.

The EASL was founded almost 50 years ago to promote and exchange science in the field of liver diseases. Its annual meeting involves the European specialists of hepatology and liver cancer and is therefore a choice opportunity to gather the European and US investigators of the ReLive clinical trial who will attend the congress.

At this occasion, an investigators meeting will take place with the clinicians involved in ReLive trial in order to review study advancement, share views and allow open discussions.

Besides, the ReLive study design, Livatag[®] phase III clinical trial, will be published as an e-poster during the 50th annual meeting of the European Association for the Study of the Liver (EASL), enhancing the awareness of the scientific community about ReLive and Livatag[®].

About Livatag[®] and About ReLive

ReLive is an international, randomized phase III trial aiming at demonstrating the efficacy and Safety of Livatag[®] (20mg/m² and 30mg/m²) versus Best standard of care (BSC) in 400 patients with advanced hepatocellular carcinoma (HCC) (primary liver cancer) after failure of intolerance to Sorafenib. More than 40% of the planned 400 patients have been recruited as of March 31, 2015, and the study is open in Europe, US and soon MENA region (Egypt, Saudi Arabia and Lebanon).

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag[®] (Doxorubicin Transdrug[™]): Phase III in hepatocellular carcinoma

Validive[®] (Clonidine Lauriad[®]): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq[®] (belinostat): Registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 15, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62